Inflazyme Pharmaceuticals Announces Escrow Closing of Private Placement: related news

Inflazyme Pharmaceuticals announces escrow closing of private placement

Inflazyme Pharmaceuticals Ltd. closes in escrow a $300,000 non-brokered unit private placement (the "Offering") for 15,000,000 (3,750,000 post-consolidation) Units (the "Units"). Each Unit consists of one common share and one warrant to purchase a common share (a "Warrant"). The Units were priced at $0.02 ($0.08 post consolidation) per Unit. Each Warrant entitles the holder to acquire one common share at a price of $0.025 ($0.10 post-consolidation) for a period of 12 months. The warrants will not be eligible for listing.

Inflazyme Pharmaceuticals Announces Escrow Closing of Private Placement

Inflazyme Pharmaceuticals Ltd. (NEX: IZP.H) announced today that it has closed in escrow a $300,000 non-brokered unit private placement (the "Offering") for 15,000,000 (3,750,000 post-consolidation) Units (the "Units"). Each Unit consists of one common share and one warrant to purchase a common share (a "Warrant"). The Units were priced at $0.02 ($0.08 post consolidation) per Unit. Each Warrant entitles the holder to acquire one common share at a price of $0.025 ($0.10 post-consolidation) for a period of 12 months. The warrants will not be eligible for listing.

Inflazyme Pharmaceuticals Announces Escrow Closing of Private Placement

Inflazyme Pharmaceuticals Ltd. (NEX: IZP.H) announced today that it has closed in escrow a $300,000 non-brokered unit private placement (the "Offering") for 15,000,000 (3,750,000 post-consolidation) Units (the "Units"). Each Unit consists of one common share and one warrant to purchase a common share (a "Warrant"). The Units were priced at $0.02 ($0.08 post consolidation) per Unit. Each Warrant entitles the holder to acquire one common share at a price of $0.025 ($0.10 post-consolidation) for a period of 12 months. The warrants will not be eligible for listing.

Inflazyme Pharmaceuticals Announces Escrow Closing of Private Placement

VANCOUVER (Marketwire) - Inflazyme Pharmaceuticals Ltd. (NEX:IZP.H) announced today that it has closed in escrow a $300,000 non-brokered unit private placement (the "Offering") for 15,000,000 (3,750,000 post-consolidation) Units (the "Units"). Each Unit consists of one common share and one warrant to purchase a common share (a "Warrant"). The Units were priced at $0.02 ($0.08 post consolidation) per Unit. Each Warrant entitles the holder to acquire one common share at a price of $0.025 ($0.10 post-consolidation) for a period of 12 months. The warrants will not be eligible for listing.

Inflazyme Pharmaceuticals Announces Escrow Closing of Private Placement

VANCOUVER, BRITISH COLUMBIA -- 06/30/08 -- Inflazyme Pharmaceuticals Ltd. (NEX: IZP.H) announced today that it has closed in escrow a $300,000 non-brokered unit private placement (the "Offering") for 15,000,000 (3,750,000 post-consolidation) Units (the "Units"). Each Unit consists of one common share and one warrant to purchase a common share (a "Warrant"). The Units were priced at $0.02 ($0.08 post consolidation) per Unit. Each Warrant entitles the holder to acquire one common share at a price of $0.025 ($0.10 post-consolidation) for a period of 12 months. The warrants will not be eligible for listing.

Inflazyme Pharmaceuticals Announces Escrow Closing of Private Placement

Vancouver, BC, July 2, 2008--(T-Net)--Inflazyme Pharmaceuticals Ltd. (NEX:IZP.H) announced today that it has closed in escrow a $300,000 non-brokered unit private placement for 15,000,000 (3,750,000 post-consolidation) Units. Each Unit consists of one common share and one warrant to purchase a common share (a "Warrant"). The Units were priced at $0.02 ($0.08 post consolidation) per Unit. Each Warrant entitles the holder to acquire one common share at a price of $0.025 ($0.10 post-consolidation) for a period of 12 months. The warrants will not be eligible for listing.

Inflazyme Pharmaceuticals Announces Escrow Closing of Private Placement

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 30, 2008) - Inflazyme Pharmaceuticals Ltd. (NEX: IZP.H) announced today that it has closed in escrow a $300,000 non-brokered unit private placement (the "Offering") for 15,000,000 (3,750,000 post-consolidation) Units (the "Units"). Each Unit consists of one common share and one warrant to purchase a common share (a "Warrant"). The Units were priced at $0.02 ($0.08 post consolidation) per Unit. Each Warrant entitles the holder to acquire one common share at a price of $0.025 ($0.10 post-consolidation) for a period of 12 months. The warrants will not be eligible for listing.

Inflazyme Pharmaceuticals Announces Escrow Closing of Private Placement

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 30, 2008) - Inflazyme Pharmaceuticals Ltd. (NEX:IZP.H) announced today that it has closed in escrow a $300,000 non-brokered unit private placement (the "Offering") for 15,000,000 (3,750,000 post-consolidation) Units (the "Units"). Each Unit consists of one common share and one warrant to purchase a common share (a "Warrant"). The Units were priced at $0.02 ($0.08 post consolidation) per Unit. Each Warrant entitles the holder to acquire one common share at a price of $0.025 ($0.10 post-consolidation) for a period of 12 months. The warrants will not be eligible for listing.

Inflazyme Pharmaceuticals Announces Escrow Closing of Private Placement

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 30, 2008) - Inflazyme Pharmaceuticals Ltd. (NEX:IZP.H) announced today that it has closed in escrow a $300,000 non-brokered unit private placement (the "Offering") for 15,000,000 (3,750,000 post-consolidation) Units (the "Units"). Each Unit consists of one common share and one warrant to purchase a common share (a "Warrant"). The Units were priced at $0.02 ($0.08 post consolidation) per Unit. Each Warrant entitles the holder to acquire one common share at a price of $0.025 ($0.10 post-consolidation) for a period of 12 months. The warrants will not be eligible for listing.

Nanotech Sciences Corp. Announces Private Placement

Nanotech Sciences Corp. ("Nanotech") (TSX VENTURE:NAN.P) is pleased to announce further advancement of its "Qualifying Transaction" in accordance with TSX Venture Exchange (the "Exchange") Policy 2.4, with Natcore Technology Inc. ("Natcore"), previously announced on June 19, 2008. Subject to completion of the Qualifying Transaction, Nanotech will raise up to $4,000,000 by way of concurrent brokered and non-brokered private placements (collectively, the "Offering") of units ("Units") at $0.40 per Unit, each Unit comprising one common share and one share purchase warrant ("Warrants"), where each Warrant is exercisable for a period of two years from closing to purchase one additional common share of Nanotech at a price of $0.75 per share. The Warrants will be subject to forcible conversion within 30 days of delivery of a notice from Nanotech

Linux Gold Corp. Completes $608,250 Private Placement at $0.15 Per Unit

VANCOUVER - (Business Wire) Linux Gold Corp. (LNXGF:OTCBB) announced today that the Company has completed a private placement of common stock and warrants raising gross proceeds of $608,250. The Company issued 4,055,000 Units, consisting of one share of restricted common stock of Linux Gold Corp. and one warrant. Each warrant will enable the investor to purchase one additional share at an exercise price of US$0.20 per share for a period of one year from the date of closing.

Linux Gold Corp. Completes $608,250 Private Placement at $0.15 Per Unit

VANCOUVER--(BUSINESS WIRE)--Linux Gold Corp. (LNXGF:OTCBB) announced today that the Company has completed a private placement of common stock and warrants raising gross proceeds of $608,250. The Company issued 4,055,000 Units, consisting of one share of restricted common stock of Linux Gold Corp. and one warrant. Each warrant will enable the investor to purchase one additional share at an exercise price of US$0.20 per share for a period of one year from the date of closing.

Elixir Pharmaceuticals Announces Exclusive Sirtuin Intellectual Property License Agreement with Boston University

Elixir Pharmaceuticals Announces Exclusive Sirtuin Intellectual Property License Agreement with Boston University

Elixir Pharmaceuticals Announces Exclusive Sirtuin Intellectual Property License Agreement with Boston University

Elixir Pharmaceuticals Announces Exclusive Sirtuin Intellectual Property License Agreement with Boston University

Private Media Group Launches Private.mobi in Spain and Germany

PRNewswire-FirstCall/ -- Private Media Group, Inc. (PRVT), a worldwide leader in premium-quality adult entertainment content, and Mobile Streams, the premier global music and media provider, today announced the launch of http://www. private. mobi in

Private Media Group Launches Private.mobi in Spain and Germany

PRNewswire-FirstCall/ -- Private Media Group, Inc. (Nasdaq: PRVT), a worldwide leader in premium-quality adult entertainment content, and Mobile Streams, the premier global music and media provider, today announced the launch of http://www. private. mobi in

Private Media Group Launches Private.mobi in Spain and Germany

BARCELONA, Spain, Aug. 6 /PRNewswire-FirstCall/ -- Private Media Group, Inc. (Nasdaq: PRVT), a worldwide leader in premium-quality adult entertainment content, and Mobile Streams, the premier global music and media provider, today announced the launch of http://www. private. mobi in Germany, Spain and South Africa as part of their strategic partnership to roll out off-portal mobile services worldwide.

Private Media Group Launches Private.mobi in Spain and Germany

BARCELONA, Spain, Aug. 6 /PRNewswire-FirstCall/ -- Private Media Group, Inc. (Nasdaq: PRVT), a worldwide leader in premium-quality adult entertainment content, and Mobile Streams, the premier global music and media provider, today announced the launch of http://www. private. mobi in Germany, Spain and South Africa as part of their strategic partnership to roll out off-portal mobile services worldwide.

Private Media Group Launches Private.mobi in Spain and Germany

BARCELONA, Spain, Aug. 6 /PRNewswire-FirstCall/ -- Private Media Group, Inc. (Nasdaq: PRVT - News), a worldwide leader in premium-quality adult entertainment content, and Mobile Streams, the premier global music and media provider, today announced the launch of http://www. private. mobi in Germany, Spain and South Africa as part of their strategic partnership to roll out off-portal mobile services worldwide.

Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)

PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced today the issuance of U.S. Patent No. 7,410,978 (the "'978 patent"), entitled "Once Daily Dosage Forms of Trospium," which is licensed exclusively to the Company by the patent's assignee, Supernus Pharmaceuticals, Inc.

Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR

LEXINGTON, Mass., August 13, 2008 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. announced today the issuance of U.S. Patent No. 7,410,978 (the "'978 patent"), entitled "Once Daily Dosage Forms of Trospium," which is licensed exclusively to the Company by the patent's assignee, Supernus Pharmaceuticals, Inc.

Online Marketing Firm Prime Visibility Moves Far up INC. Magazine's 2008 List of 5000 Fastest Growing Private CompaniesInc. 5000 The Fastest Growing Private Companies in America

Online Marketing Firm Prime Visibility Moves Far up INC. Magazine's 2008 List of 5000 Fastest Growing Private CompaniesInc. 5000 The Fastest Growing Private Companies in America

Barr Announces Agreements to Settle Mirapex(R) and Aggrenox(R) Patent Challenges

PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) announced today that its Barr Laboratories subsidiary has signed a Settlement Agreement and a License Agreement with Boehringer Ingelheim to resolve the patent litigation involving Boehringer Ingelheim's Mirapex(R) product. Separately, Barr Laboratories entered into a Settlement Agreement and a Supply Agreement to resolve the patent litigation regarding Boehringer Ingelheim's Aggrenox(R) product and Duramed Pharmaceuticals, a subsidiary of Barr Pharmaceuticals, entered into a Co-Promotion Agreement with Boehringer Ingelheim relating to Aggrenox(R).

Barr Announces Agreements to Settle Mirapex(R) and Aggrenox(R) Patent Challenges

MONTVALE, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL - News) announced today that its Barr Laboratories subsidiary has signed a Settlement Agreement and a License Agreement with Boehringer Ingelheim to resolve the patent litigation involving Boehringer Ingelheim's Mirapex® product. Separately, Barr Laboratories entered into a Settlement Agreement and a Supply Agreement to resolve the patent litigation regarding Boehringer Ingelheim's Aggrenox® product and Duramed Pharmaceuticals, a subsidiary of Barr Pharmaceuticals, entered into a Co-Promotion Agreement with Boehringer Ingelheim relating to Aggrenox®.

Search took 0.14 seconds.